Ear atresia: Is there a role of apoptosis-regulating miRNAs?

**Ezgi Aslan,1 Emre Akbas,1 Sena Yilmaz,1 Ahmet Salih Karaoglu,1 Ubyede Telli,1 Salih Yildirim,1 Hilal Gudek,1 Mahmut Tayyar Kalioglu,2 Sarenur Yilmaz,2 Ibrahim Akalin3**

1Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
2Department of Otorhinolaryngology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
3Department of Medical Genetics, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey

**ABSTRACT**

**OBJECTIVE:** The molecular events underlying ear development involve numerous regulatory molecules; however, the role of microRNAs (miRNAs) has not been explored in patients with ear atresia. Here, we aimed to investigate the expressions of 20–22 nucleotide noncoding RNAs.

**METHODS:** We selected 12 miRNAs that function to control post-transcriptional gene expression in different pathways, including apoptosis, angiogenesis, and chondrogenesis. The altered miRNA expressions were analyzed by real-time PCR from serum samples of 7 patients with ear atresia and 8 controls.

**RESULTS:** We found that the expression of apoptosis-regulating miRNAs was significantly downregulated in patients with ear atresia. The expressions of miR126, miR146a, miR222, and miR21 were significantly decreased by 76.2-(p=0.041), 61.8-(p=0.000), 30.5-(p=0.009), and 71.21-fold (p=0.042), respectively, compared with controls.

**CONCLUSION:** Abnormal ear development in ear atresia patients, could possibly be due to the reduced expression of apoptosis regulating miRNAs. Changes in the regulation of tumor protein p53 (TP53), p53 upregulated modulator of apoptosis (PUMA), Fas cell surface death receptor (FAS), FAS ligand (FasL), and phosphatase and tensin homolog (PTEN) directly or within the apoptosis-related cascades may play important roles during development, particularly in the external ear. This is the first report to present the possible association between apoptosis-regulating miRNAs and ear atresia/microtia.

Keywords: Apoptosis; ear atresia; miRNA; miR21; miR146a; miR222.

Ear atresia is a spectrum of ear deformities, commonly coexisting with unilateral or bilateral microtia (MIM 600674, MIM 251800). Its prevalence is between 0.8 and 17.4 in 10,000 individuals in different populations [1, 2]. It involves the failure of the development of the external auditory canal (EAC), and its surgical treatment is considered to be one of the most complex and demanding surgeries in otorhinolaryngology. Moreover, this malformation may be associated with other congenital anomalies, including the CHARGE syndrome [3, 4]. Development of the ear is a continuous complex process that begins during early embryonic life within three compartments and is completed till the first decade [5]. Briefly, in the 4th to 5th week of embryogenesis, the ectoderm of the first branchial groove elongates to form the primitive EAC and oppose to the endoderm of the first pharyngeal pouch to form a prototympanic membrane where the mesoderm intervenes between them thereafter. By this time, the epithelial plate produced by the proliferation of the ectodermal cells lining the primitive

**Received:** August 02, 2017  **Accepted:** December 11, 2017  **Online:** September 13, 2018

**Correspondence:** Dr. Ibrahim AKALIN. Istanbul Medeniyet Universitesi Tip Fakultesi, Tibbi Genetik Anabilim Dalı, Istanbul, Turkey. Phone: +90 216 595 40 00 e-mail: ibrahimakalin@yahoo.com

© Copyright 2018 by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com

doi: 10.14744/nci.2017.26680
EAC first occludes the primitive EAC in the 8th week of gestation and is eventually split by apposed epithelial cells for subsequent recanalization to secondary EAC by approximately 19th–21st week of gestation. Toward the end of the 28th week, the tissue is progressively absorbed from the tympanic space and branchial groove to open the external canal in essence with the remaining tympanic membrane [6] and closely allied with the development of the middle ear space and ear bones from the branchial apparatus [7, 8].

The remarkable role of programmed cell death, the so-called apoptosis, in ear development has been deduced by advances in recent technology. It aids in normal development by eradicating unwanted cells during morphogenesis. Neural tube, palate, heart, duodenal mucosa, and limb bud are the clarified examples in which apoptosis occurs [9, 10]. Likewise, Nishizaki et al. [8] (1998) showed that apoptosis is involved in the mouse EAC development.

Microribonucleic acids (miRNAs) are highly conserved, small, noncoding RNA molecules, which are approximately 21–24 nucleotides in length, and control post-transcriptional gene expression in a wide variety of cellular processes, including cell proliferation, differentiation, cell fate determination, signal transduction, organ development, angiogenesis, tumorigenesis, and apoptosis [11–13]. Many miRNAs are involved in regulating either intrinsic or extrinsic apoptotic pathways [14].

The normal development of the ear consists of complex succession of events occupying three embryonic germ cell layers. Factors leading to ear atresia by ceasing the contemporaneous aural developmental course are yet to be clarified. Nishikazi et al. [8] (1998) showed that in mouse, the apposed epithelium of EAC is eliminated by apoptosis. Hence, in this study, we aimed to investigate the expression of miRNAs regulating several pathways, including apoptosis, and for the first time achieved significantly altered expressions of miRNAs in the serum of patients with ear atresia, up to the literature.

**MATERIALS AND METHODS**

**Patient and control groups and miRNA**

In our study, we included 7 patients and 8 controls who were age- and sex-matched after obtaining local ethical committee approval (2013–0007) and informed consents. The mean age of the patients was 14.3±7.9 years (minimum, 5 years; maximum, 27 years). Four patients had unilateral ear atresia, while the rest had bilateral ear atresia. The investigated miRNAs regulating different mechanisms are shown in Table 1.

**Isolation of miRNA-enriched total RNA**

MiRNAs were isolated from the serum samples of the patients and controls using the miRNeasy Serum/Plasma Kit (Qiagen) according to manufacturer’s instructions. Briefly, 1 ml of QIAzol Lysis Reagent was added to 200 µl of the serum sample by pipetting up and down for efficient lysis of fatty and standard tissues before RNA isolation. The homogenate was incubated at room temperature for 5 minutes. Then, 3.5 µl of miRNeasy Serum/Plasma Spike-In Control (at 1.6 × 108 copies/µl) was added and mixed thoroughly. Next, 200 µl chloroform was added to

---

**Table 1. miRNA regulating different mechanisms in ear atresia**

| miRNA       | Apoptosis Regulator | Endodermal Developer | Angiogenesis | Chondrogenesis |
|-------------|---------------------|----------------------|--------------|---------------|
| hsa-mir-143 | X                   |                      |              |               |
| hsa-mir-146a| X                   |                      |              |               |
| hsa-mir-92a | X                   |                      |              |               |
| hsa-mir-181b| X                   |                      |              |               |
| hsa-mir-210 | X                   |                      |              |               |
| hsa-mir-106b| X                   |                      |              |               |
| hsa-mir-183 | X                   |                      |              |               |
| hsa-mir-375 | X                   |                      | X            |               |
| hsa-mir-126 |                      |                      |              | X             |
| hsa-mir-222 | X                   |                      |              |               |
| hsa-let-7f  |                      |                      |              | X             |
| hsa-mir-21  | X                   |                      |              |               |
the lysate tube, vortexed for 15 seconds, and incubated at room temperature for 2 minutes. This was followed by the separation of the phases by centrifugation at 12000 × g at 4°C for 15 minutes. Then, 600 µl of the upper aqueous phase was transferred to a new collection tube by avoiding the transfer of any interphase solution. Ethanol (900 µl) was added and mixed thoroughly using a pipette. Next, 700 µl of the sample was added onto an RNeasy MiniElute spin column in a 2-ml collection tube and centrifuged at ≥8000 × g for 15 seconds at room temperature. Buffers RWT (700 µl), and RPE (500 µl) and 80% ethanol (500 µl) prepared with RNase-free water were added to the RNeasy MiniElute spin column and centrifuged for 15 seconds at ≥8000 × g, followed by additional 2 minutes of centrifugation at full speed for 5 minutes to dry the membrane. The filtrate and collection tube were discarded at each step. Finally, the microRNA-enriched total RNA was eluted by centrifugation for 1 minute at full speed using 14 µl of RNase-free water.

Complementary DNA (cDNA) synthesis

cDNA was randomly primed using miScript II Reverse Transcription (RT) Kit (Qiagen) using 5 µg of miRNA-enriched total RNA. Briefly, RT-PCR was set up with 4 µl of 5 × miScript HiSpec Buffer, 2 µl of 10 × Nucleic Mix, 1 µl of miScript Reverse Transcriptase Mix, 8 µl of RNase-free water, and 5 µl of template RNA in a 20-µl reaction tube. Reverse transcription was carried out at 37°C for 60 minutes and 95°C for 5 minutes. cDNA was then diluted with 200 µl of nuclease free water for further use in real-time polymerase chain reaction (RT-PCR).

RT-PCR

Mature miRNAs were expressed using Rotor-Gene® Q instrument with software 2.1.0.9 and quantitative RT-PCR (RT-qPCR) with QuantiTect SYBR Green PCR Kit (Qiagen). RT-PCR was performed in duplicate after optimization, including minus reverse transcription controls to assess any DNA and nontemplate controls for ensuring the lack of background signal. The RT-PCR reaction was set up with mild modifications of manufacturer’s instructions as follows: 5 µL of 2 × QuantiTect SYBR Green PCR Master Mix, 1 µL of 10 × miScript Universal Primer, 1 µL of 10 × primer assay, and 1 µL of RNase-free water. Thirteen miRNAs covering a variety of miRNA sequence features (Table 1), including Ce miR-39, were selected, and SNORD61, SNORD68, and SNORD95 were used as housekeeping genes.Shortly after the hot start Taq polymerase activation at 95°C for 10 minutes, reaction was carried out with 40 cycles of 95°C for 15 seconds, 55°C for 30 seconds, and 72°C for 15 seconds, followed by melting reaction ramps from 55°C–95°C at the acquisition of Melt A on Green. For TP53 mRNA expression, forward and reverse primers 5’-CGACAGGAGGAGATCTCCATCTCAA-3’ and 5’-GCCCAATTGCAGGTAAAACAGTC-3’ were used, respectively.

Data analysis and statistics

The threshold was manually determined as 0.025 in all the reactions, and standards were imported from the previous study as conc = 10⁻⁰.³²₈ × Ct + 11.903 with cycle threshold (Ct) values of −3.050 × log(conc) + 36.302 and R² of 0.99974. Ct values of miRNA expressions were exported from the instrument after normalization with dynamic tube using slope correct options of the real-time cycler software. Ct values and calculated concentrations according to the standards were entered into an Excel spreadsheet, and the average Ct value was converted to quantities for SABiosciences analysis. The quality of expended mature miRNAs was checked with melt analyses on Green. Then, the Ct data of miRNAs and TP53 mRNA were analyzed according to fold change [2⁻ΔΔCT] using online miScript miRNA PCR Array Data Analysis Tool (www.qiagen.com). For TP53 mRNA expression analyses, the Student’s t-test was used. A p-value of 0.05 was considered statistically significant.

RESULTS

RT-qPCR analysis of serum miRNA

To explore the possible effects of microRNAs in the ear atresia, 13 microRNA expression profiles were analyzed in the serum of patients and control group. We found the expression patterns of pro-apoptotic microRNA’s downregulated in the patients. Among them, miR-126, miR-146a and miR-222 and miR-21 were significantly 76.2 (p=0.041), 61.8 (p=0.000), 30.5 (p=0.009) and 71.21 (p=0.042) fold decreased compared to controls, respectively (Table 2 and Fig. 1).

TP53 mRNA expression analysis

To explore the effects of downregulated pro-apoptotic miRNAs on apoptosis, we analyzed the expression levels of TP53 mRNA in the patient’s serum. We found that TP53 mRNA expression was significantly downregulated (31.7-fold; p=0.036; CI95%, 0.00001–0.09) in patients with ear atresia compared with controls. (Figs. 2, 3).
DISCUSSION

The underlying effect of miRNA on the development of ear atresia was our major query in this study. Because miRNAs have an essential role in the developmental processes, including organogenesis, we aimed to explore a possible association between miRNAs regulating inflammation, apoptosis, angiogenesis, and chondrogenesis and ear atresia to detect whether any miRNA could be responsible for the developmental defects in ears (Table 1). Here, we noticed that there was a significant expression difference for several miRNAs between patients and healthy controls. Because the ears continue to develop during the lifetime [5], and ear atresia not only presents with external ear anomaly or microtia but also affects middle and inner compartments, we decided to use the serum samples of patients to investigate miRNA expression levels at the time of diagnoses instead of taking biopsy samples from the patients’ external ear. We found that the expressions of four miRNAs miR222, miR146a, miR126, and miR21 among the 12 miRNAs were significantly downregulated in patients with ear atresia. Remarkably, these miRNAs are particularly known to regulate apoptosis in human cancers.

Few studies in the literature have addressed the ques-

---

**Table 2.** Fold-regulation results and p-values of miRNAs expression levels of the ear atresia and control groups. Statistically significant and lower miRNAs expressions according to the control group are indicated with ‘‘a’’ symbol and ‘‘−’’ respectively.

| miRNA       | Fold Change Ear Atresia/Control | 95% CI          | Fold Regulation Ear Atresia/Control | p     |
|-------------|---------------------------------|-----------------|-------------------------------------|-------|
| hsa-mir-39ce| 1                               | (1.00-1.00)     | 1                                   | 0     |
| hsa-mir-143 | 0.37                            | (0.00001-0.90)  | -2.7                                | 0.34  |
| hsa-mir-210 | 2.66                            | (0.00001-9.28)  | 2.6                                 | 0.96  |
| hsa-mir-375 | 0.03                            | (0.00001-0.06)  | -33.8                               | 0.11  |
| hsa-mir-146a| 0.02                            | (0.00001-0.04)  | -61.8a                              | 0.0003a|
| hsa-mir-222a| 0.03                            | (0.00001-0.09)  | -30.5a                              | 0.009a|
| hsa-mir-106b| 0.31                            | (0.00001-0.80)  | -3.1                                | 0.31  |
| hsa-let-7f  | 0.70                            | (0.00001-3.06)  | -1.4                                | 0.21  |
| hsa-mir-183 | 0.59                            | (0.00001-1.57)  | -1.7                                | 0.35  |
| hsa-mir-181b| 0.24                            | (0.00001-0.74)  | -4.1                                | 0.14  |
| hsa-mir-126a| 0.01                            | (0.00001-0.04)  | -76.2a                              | 0.041a|
| hsa-mir-92a | 0.01                            | (0.00001-0.02)  | -130                                | 0.07  |
| SNORD68     | 1.04                            | (0.00001-2.89)  | 1                                   | 0.36  |
| hsa-mir-21a | 0.014a                          | (0.00001-0.04)  | -71.2a                              | 0.042a|
| SNORD61     | 1.55                            | (0.18-2.93)     | 1.55                                | 0.79  |

CI: Confidence Interval

**Figure 1.** Clustergram of miRNA expressions in patients with ear atresia compared with controls. This clustergram was created with online QIAGEN miScript Primer Assay, Data Analysis Center. Accordingly, expression levels of 10 miRNAs were decreased (green) in the patients compared with the control group (red). The decreased expression levels of miR146a (p=0.000), miR222 (p=0.009), and miR126 (p=0.041) were statistically significant.
To discuss in more detail, the extrinsic apoptotic pathway starts with binding of FasL (death Ligand) to its receptor (Fas), and FasL has been reported to be a direct target of miR21 [14]. It has been reported that by targeting FasL, serum miR21 serves as a predictor for chemosensitivity and chemoresistance in advanced pancreatic cancers [20]. Moreover, miR21 promotes cell survival by inhibiting FasL expression in acute myeloid leukemia. Because we significantly found miR21 to be 71.2-fold downregulated (95% CI: 0.00001–0.04, p=0.042), decreased inhibition of FasL due to underexpression of miR21 could activate the apoptosis cascade through the initial step of the extrinsic apoptotic pathway. Moreover, miR21 has been reported to control the key regulators of apoptosis, such as SMAD proteins, which are the critical mediators of tumor growth factor beta (TGF-β)-induced pro-apoptotic signaling. By binding to the 3′- untranslated region (3′-UTR) of SMAD7 mRNA, miR21 inhibits its translation [21]. Thus, decreased inhibition of SMAD7 mRNA could directly result in increased apoptosis.

Another anti-apoptotic miRNA was miR146a, and together with miR196b, functioned as a potent suppres-
Aslan et al., Apoptosis regulating miRNAs in ear atresia

outer ear malformations besides coloboma, heart outflow tract defects, and craniofacial defects [26]. They reported that p53 mutant protein could stabilize or hyperactivate wildtype p53 to inappropriately induce apoptosis during development. Moreover, they stated that due to CHD7 binding to the p53 promoter, thereby causing inappropriate p53 activation due to CHD7 loss, could contribute to CHARGE syndrome phenotypes [26]. According to these striking findings [26] and few published data supporting the critical role for p53 in developmental processes of ears [8], we speculated that dysregulation of p53 through the downregulation of apoptosis-controlling miRNAs (miR21, miR146, miR126, and miR222) by altering the timing or intensity of apoptosis, particularly in the outermost epithelial cells during auditory meatal development [8], may beget the ear abnormalities, including ear atresia and/or microtia (Fig. 4).

In addition, defects in cell migration or cell death could be attributed to underlying mechanisms for congenital diseases during the developmental process of embryogenesis [24, 25]. CHARGE syndrome is a multiple anomaly disorder that presents with a variety of phenotypes besides ear abnormalities [4]. Although 70%–90% of CHARGE syndrome case result from mutations in ATP-dependent chromatin remodeler CHD7 gene, Van Nostrand et al. (2014) showed surprising results using a knock-in mutant mouse strain expressing a stabilized and transcriptionally dead variant of the p53 tumor suppressor protein along with a wildtype p53 allele. They stated that the embryos represented characteristic phenotypes of CHARGE syndrome, including inner and outer ear malformations besides coloboma, heart outflow tract defects, and craniofacial defects [26]. They reported that p53 mutant protein could stabilize or hyperactivate wildtype p53 to inappropriately induce apoptosis during development. Moreover, they stated that due to CHD7 binding to the p53 promoter, thereby causing inappropriate p53 activation due to CHD7 loss, could contribute to CHARGE syndrome phenotypes [26]. According to these striking findings [26] and few published data supporting the critical role for p53 in developmental processes of ears [8], we speculated that dysregulation of p53 through the downregulation of apoptosis-controlling miRNAs (miR21, miR146, miR126, and miR222) by altering the timing or intensity of apoptosis, particularly in the outermost epithelial cells during auditory meatal development [8], may beget the ear abnormalities, including ear atresia and/or microtia (Fig. 4).

Furthermore, miR21 can affect cells by regulating major cascades of autophagy. Autophagy is a cellular pathway for the degradation of long-lived proteins and cytoplasmic organelles in its own lysosomal system in eukaryotic cells. Different signaling pathways, including

![Figure 4](image-url)

**Figure 4.** Representation of downregulated miRNAs resulting in ear atresia through the regulation of the apoptosis pathway. The significantly decreased expressions of miRNAs (miR21, miR146a, miR126, and miR222) may be related with apoptotic pathways in the pathogenesis of ear atresia.
mammalian target of rapamycin (mTOR), phosphatidylinositol 3-kinase-I (PI3K-I)/PKB, Ras GTases, calcium, and protein synthesis, play important roles in regulating autophagy [27, 28]. PTEN, a negative regulator of the PI3K signaling pathway, is a hot target for a number of miRNAs, including miR21, which are involved in the regulation of several cancer types [29, 30]. By the downregulation of miR21, PTEN more actively participates as a negative regulator of the PI3K signaling pathway [14]. Additionally, miR21 controls the major members of the Ras-Raf-1-MEK1/2-ERK1/2 signaling pathway [31, 32], particularly Ras expression in tumor suppression. Decreased expression of miR-21 may also serve as the negative regulator for autophagy either through Ras or PTEN within the cascade.

miR222 is encoded in tandem on the Xp11.3 chromosome in humans and is highly conserved in vertebrates similar as pri-miRNA of miR221 [33]. The tumor suppressor and angiogenesis genes have been identified as miR221/222 targets in several cancers [34]. Polliseno reported that miR221/222 family modulates the angiogenic activity of stem cell factor by targeting its receptor c-Kit and consequently promotes invasion and metastasis [28]. In other study, miR222 was reported to directly induce apoptosis by targeting the binding sites on mRNA 3’-UTR of mitochondrial apoptotic protein PUMA, which has recently been identified as a critical mediator of p53-associated apoptosis [35]. Hence, based on our results, we assumed that the downregulation of miR222 could be related to ear atresia by leading over-induced apoptosis through excessive activity of PUMA on mitochondrial apoptotic pathway. In case of the downregulation of PUMA repressing factors, such as miR222, more apoptosis than it necessitates may have occurred during external and middle ear development. At this point, p53 could be a good mediator associated with miR222 and PUMA; however, we found its expression significantly decreased in the ear atresia patient group (Fig. 2).

Thus, we assert that ear atresia may also develop due to increased apoptosis in concurrence with decreased autophagy. However, how can decreased autophagy result in ear atresia? PUMA is a direct transcriptional target of p53 and binds Bcl-2, which is localized in the mitochondria, induces cytochrome c release, and activates the rapid induction of apoptosis [36]. In our study, p53 was significantly downregulated; therefore, we assumed that downregulation of miR222 may activate PUMA regardless of p53.

Finally, miR126 is a cell growth suppressor that targets IRS-137, and ectopic expression of miR126 in SGC-7901 gastric cancer cells potently inhibits cell growth by inducing cell cycle arrest in the G0/G1 phase. miR126 may also lead to the inhibition of migration and invasion in vitro as well as tumorigenicity and metastasis in vivo [38]. Taken together, our results suggested that the possible causes of ear atresia may include underexpression of miR126 by improper migration and timing of apoptotic cells. Thus, decreased expressions of apoptosis-controlling miRNAs may lead to inappropriate apoptosis at inappropriate settling in the ear.

CONCLUSION

The pathways underlying the development of ear atresia with diverse phenotypes remain poorly understood. With our study, we for the first time reported the significantly decreased expressions of miRNAs (miR21, miR146a, miR126, and miR222) in the serum of patients with ear atresia, thus suggesting that miRNA-mediated control of apoptotic pathways may be responsible for the pathogenesis of ear atresia. Further studies are needed to identify the effects of miRNAs and their target genes in altered developmental processes.

Acknowledgment: This project was supported by the Research Fund of Istanbul Medeniyet University Project # TSG-2013-333. We would like to thank Associate Prof. Serdar Ceylaner, MD, for his kind supply of the TP53 forward and reverse primers used in RT-PCR experiments. Among the authors, EA, EA, SY, ASK, UT, SY, and HG are members of the Project Machine as Medical Students. The authors declare no conflict of interest.

Conflict of Interest: The authors declare no conflict of interest.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship Contributions: Concept – I.A., S.Y., M.T.K., E.As., E.A.; Design – I.A., E.As., A.S.K.; Supervision – I.A., M.T.K.; Materials – M.T.K., I.A.; Data collection &/or processing – E.As., E.A., S.Y., A.S.K., U.T., S.Y., H.G., M.T.K., I.A.; Analysis and/or interpretation – E.As., E.A., S.Y., A.S.K., U.T., S.Y., H.G., I.A.; Writing – E.As., E.A., S.Y., U.T., M.T.K., I.A.; Critical review – E.A., I.A.

REFERENCES

1. Nager GT. Congenital aural atresia: anatomy and surgical management. Birth Defects Orig Artic Ser 1971;07:33–51.
2. Castilla EE, Orioli IM. Prevalence rates of microtia in South America. Int J Epidemiol 1986;15:364–8.
3. Dostal A, Nemecova J, Gaillyova R, Vranova V, Zezulkova D, Lejska M, et al. Identification of 2.3-Mb gene locus for congenital aural atresia
Aslan et al., Apoptosis regulating miRNAs in ear atresia

10. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 1990; 67: p. 77–87.

9. Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death. Diag Pathol 2014; 9:1621–6.

8. Nishizaki K, Anniko M, Orita Y, Masuda Y, Yoshino T, Kanda S, et al. Programmed cell death in the development of the mouse external auditory canal. Anat Rec 1998; 252: 378–82.

7. Kenna MA. Embryology and developmental anatomy of the ear. In: Bluestone CD, Stool SE, editors. 2nd ed. Philadelphia: WB Saunders; 1990. p. 77–87.

6. Peck JE. Development of hearing. Part II. Embryology. J Am Acad Audiol 1994; 5: 359–65.

5. Wright CG. Development of the human external ear. J Am Acad Audiol 1997; 8: 379–82.

4. Jones KL, Jones MC, Del Campo M. Smith’s recognizable patterns of human malformations. 7th ed. Philadelphia: Elsevier Saunders; 2013.

3. Kersigo J, D’Angelo A, Gray BD, Soukup GA, Fritsch B. The role of sensory organs and the forebrain for the development of the craniofacial shape as revealed by Foxg1-cre-mediated microRNA loss. Genesis 2011; 49: 326–41.

2. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597–610.

1. Nishizaki K, Anniko M, Orita Y, Masuda Y, Yoshino T, Kanda S, et al. Programmed cell death in the development of the mouse external auditory canal. Anat Rec 1998; 252: 378–82.

0. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 1990; 67: p. 77–87.

Aslan et al., Apoptosis regulating miRNAs in ear atresia

11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–97.

10. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 1993; 67: 205–8.

9. Gerschenson LE, Rotello RJ. Apoptosis: a different type of cell death. Diag Pathol 2014; 9:1621–6.

8. Nishizaki K, Anniko M, Orita Y, Masuda Y, Yoshino T, Kanda S, et al. Programmed cell death in the development of the mouse external auditory canal. Anat Rec 1998; 252: 378–82.

7. Kenna MA. Embryology and developmental anatomy of the ear. In: Bluestone CD, Stool SE, editors. 2nd ed. Philadelphia: WB Saunders; 1990. p. 77–87.

6. Peck JE. Development of hearing. Part II. Embryology. J Am Acad Audiol 1994; 5: 359–65.

5. Wright CG. Development of the human external ear. J Am Acad Audiol 1997; 8: 379–82.

4. Jones KL, Jones MC, Del Campo M. Smith’s recognizable patterns of human malformations. 7th ed. Philadelphia: Elsevier Saunders; 2013.

3. Kersigo J, D’Angelo A, Gray BD, Soukup GA, Fritsch B. The role of sensory organs and the forebrain for the development of the craniofacial shape as revealed by Foxg1-cre-mediated microRNA loss. Genesis 2011; 49: 326–41.

2. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597–610.

1. Nishizaki K, Anniko M, Orita Y, Masuda Y, Yoshino T, Kanda S, et al. Programmed cell death in the development of the mouse external auditory canal. Anat Rec 1998; 252: 378–82.

0. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 1993; 67: 205–8.